Dose-Response of Gonadal Steroids and Bone Turnover in Older Men

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

177 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-09-30

Study Completion Date

2017-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the levels of testosterone and/or estradiol at which changes in bone turnover, body composition, strength, sexual function etc. begin to occur in older men. This information may help determine when to intervene with hormone replacement therapy in aging men.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Testosterone Effects on Bone and Frailty

NCT00182871

Aging Frailty Osteoporosis

COMPLETED PHASE4

Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.

NCT00104572

Hypogonadism Diabetes Sarcopenia +2 more

COMPLETED PHASE2

Anastrozole Administration in Elderly Hypogonadal Men

NCT00136695

Hypogonadism

COMPLETED PHASE2

Cycled Testosterone Replacement Study

NCT00957528

Hypogonadism

COMPLETED PHASE1

Does Testosterone Improve Function in Hypogonadal Older Men

NCT00304213

Hypogonadism

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this protocol, men age 60-75 will be randomized to one of 6 groups. Groups 1-5 will receive goserelin acetate (Zoladex) plus 0 (placebo gel), 1.25, 2.5, 5, or 10\* g/day of testosterone gel (Androgel). Group 6 will receive placebos for both goserelin acetate and testosterone gel. (\*Note that the 10 g/day dose was reduced to 7.5 g/day part-way through the trial due to reports of possible increased risk of cardiovascular events with testosterone administration).

Subjects will be blinded with respect to group assignment. Dietary calcium intake will be assessed by a research dietitian and adjustments made through diet or supplements so that calcium intake is between 1000 and 1200 mg/day.

Subjects will be seen on the Clinical Research Center at 4 week intervals for 16 weeks (0, 4, 8, 12, and 16 weeks). At each visit, compliance with Androgel will be assessed by reviewing a medication diary. A standardized series of questions will be posed to each subject to assess potential side effects of the study drugs. Subjects receiving Androgel' will be given a new 4 week supply of medication (except at week 16). A fasting blood and second voided urine sample will be collected. After the blood and urine samples have been obtained, subjects will be given their goserelin injection. The blood and urine tests listed below as well as anthropometric measures, and questionnaires will be performed at each visit. Dual-energy x-ray absorptiometry (DXA), quantitate computed tomography (QCT) scans, and strength assessments will be performed at 0 and 16 weeks only. Subjects who discontinue participation at or after week 8 will be asked if they are willing to have an early discontinuation visit in which all procedures normally done at week 16 will be performed.

The following measures will be assessed:

* Routine chemistries and prostate specific antigen, PSA (for safety assessment)
* Bone turnover using blood and urine tests
* Hormones
* Lipids
* Body composition
* Strength
* Sexual desire and erectile function
* Bone mineral density and bone microarchitecture

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: 0 g/day

Zoladex plus Placebo Testosterone (T) gel

Group Type EXPERIMENTAL

Testosterone

Intervention Type DRUG

Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day

Goserelin acetate

Intervention Type DRUG

3.6 gms sc every 4 weeks

Group 2: 1.25 g/day

Zoladex plus 1.25 g/day T gel

Group Type EXPERIMENTAL

Testosterone

Intervention Type DRUG

Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day

Goserelin acetate

Intervention Type DRUG

3.6 gms sc every 4 weeks

Group 3: 2.5 g/day

Zoladex plus 2.5 g/day T gel

Group Type EXPERIMENTAL

Testosterone

Intervention Type DRUG

Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day

Goserelin acetate

Intervention Type DRUG

3.6 gms sc every 4 weeks

Group 4: 5 g/day

Zoladex plus 5 g/day T gel

Group Type EXPERIMENTAL

Testosterone

Intervention Type DRUG

Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day

Goserelin acetate

Intervention Type DRUG

3.6 gms sc every 4 weeks

Group 5: 10* g/day

Zoladex plus 10\* g/day T gel. \*Note that the 10 g/day dose was reduced to 7.5 g/day part-way through the trial

Group Type EXPERIMENTAL

Testosterone

Intervention Type DRUG

Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day

Goserelin acetate

Intervention Type DRUG

3.6 gms sc every 4 weeks

Group 6: Placebo/Placebo (PBO/PBO)

Placebo Zoladex plus Placebo T gel (controls)

Group Type EXPERIMENTAL

Testosterone

Intervention Type DRUG

Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day

Goserelin acetate

Intervention Type DRUG

3.6 gms sc every 4 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Testosterone

Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day

Intervention Type DRUG

Goserelin acetate

3.6 gms sc every 4 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Androgel Zoladex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy men age 60 to 75

Exclusion Criteria

* History of significant cardiac, renal, pulmonary, hepatic, benign prostatic hyperplasia, or malignant disease, current alcohol or illicit drug abuse, or major psychiatric disorders.
* Current diagnoses of disorders known to affect bone metabolism including hyperthyroidism, hyperparathyroidism, osteomalacia, or Paget's disease.
* Current use of medications known to affect bone metabolism including estrogens, androgens, anti-estrogens, bisphosphonates, calcitonin, fluoride, oral or inhaled glucocorticoids, suppressive doses of thyroxine, lithium, pharmacological doses of vitamin D (greater than 2000 IU/day), or anti-convulsants.
* Cognitive or intellectual impairment that precludes complete understanding of the study protocol.
* History of deep vein thrombosis, pulmonary embolism, or clotting disorders.
* Serum 25-hydroxyvitamin D \< 15 ng/mL
* Serum parathyroid hormone (PTH) \< 10 or \> 65 pg/mL
* Serum thyroid stimulating hormone (TSH) \< 0.5 or \> 5.0 U/L
* Serum calcium \> 10.6 mg/dL
* Serum creatinine \> 2 mg/dL
* Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \> 2x the upper limit of normal
* Serum bilirubin \> 2 mg/dL
* Serum alkaline phosphatase \> 150 U/L
* Plasma hemoglobin \< 11 gm/dL
* Hematocrit \> 50
* Fracture within the last 6 months.
* Serum testosterone level \< 270 or \> 1070 ng/dL
* Serum prostate specific antigen (PSA) level \> 4 ug/L.
* International Prostate Symptom Score (IPSS) \> 19
* Systolic blood pressure \> 160 or diastolic blood pressure \> 95
* Framingham risk score greater than or equal to 20
* Difficulty walking 2 blocks

Minimum Eligible Age

60 Years

Maximum Eligible Age

75 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes